Dr. Campbell current MD and CEO of Partrys was previously the COO and CFO of ChemGenex Pharmaceuticals Limited (ASX:CXS), with responsibilities ranging from business development through to IP management and including finance and governance . As a member of the ChemGenex executive team he helped transform a research-based company with a market capitalisation of approximately A$10M to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011, ChemGenex was sold to Cephalon for A$230M.
Currently we are at MC of Circa $8. He must have seen something in PAB product and must be confident enough to turn this around.
cheers
J
Dr. Campbell current MD and CEO of Partrys was previously the...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
